.After elevating $170 thousand back in February, metabolic disease-focused BioAge Labs has submitted to debut on the public market.The Eli Lilly-partnered biotech plan to detail on the Nasdaq under the sign “BIOA,” according to documents filed along with the Securities and also Swap Payment. The provider has not openly discussed an anticipated financial volume for the offering.The clinical-stage company promotes lead candidate azelaprag, a by mouth delivered tiny molecule slated to go into stage 2 screening in combo along with semaglutide– marketed by Novo Nordisk under brand name Wegovy for weight reduction– in the 1st fifty percent of next year. Semaglutide is actually additionally offered as Ozempic and also Rybelsus by Novo for diabetic issues.
Apelin receptor agonist azelaprag is created to integrate well with GLP-1 drugs, boosting fat burning while preserving muscle mass. The investigational drug was discovered to become well-tolerated one of 265 individuals all over 8 phase 1 tests, according to BioAge.Recently, BioAge gathered the support of Lilly to manage a test mixing azelaprag with the Significant Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is actually marketed for diabetic issues as Mounjaro as well as Zepbound for fat loss. The companions are presently administering a period 2 trial of azelaprag and also tirzepatide, with topline outcomes assumed in the third fourth of 2025.The biotech is actually also considering an insulin sensitiveness proof-of-concept trial evaluating azelaprag as a monotherapy in the initial half of next year to assist possible evidence growth.
On top of that, the firm organizes to ask the FDA for authorization in the 2nd one-half of 2025 to introduce individual screening for an NLRP3 inhibitor targeting metabolic ailments and also neuroinflammation.BioAge’s expected transfer to everyone market follows a small uptick in prepared biotech IPOs from Bicara Rehabs as well as Zenas Biopharma. Zooming out, the latest IPO landscape is actually a “blended image,” along with premium firms still debuting on everyone markets, merely in minimized numbers, according to PitchBook.